Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 25;5(3):182-190.
doi: 10.1002/agm2.12216. eCollection 2022 Sep.

A consolidated review on stem cell therapy for treatment and management of Alzheimer's disease

Faizan Ahmad  1 , Punya Sachdeva  2
Affiliations
Review

A consolidated review on stem cell therapy for treatment and management of Alzheimer's disease

Faizan Ahmad et al. Aging Med (Milton). .

Abstract

Alzheimer's disease (AD) is one of the most common forms of dementia and affects around 50 million people around the globe. AD is diagnosed mainly through imaging techniques and to date only five drugs are approved for management of AD but no promising treatment is available for AD. So in this review, we are focusing on stem cell therapy for AD. This review will cover all stem cells like mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, and neural stem cells. Clinical trials of AD have also been discussed. Finally, limitations of stem cells are discussed with ongoing clinical trials, and in the future stem cell therapy can be used for treatment of AD.

Keywords: Alzheimer's disease; Induced pluripotent stem cells; embryonic stem cells; mesenchymal stem cells; neural stem cells.

PubMed Disclaimer

Conflict of interest statement

The authors declare they have no conflict of interest.

Figures

FIGURE 1
FIGURE 1
Various stem cells are used to combat Alzheimer's disease‐like Bone marrow‐derived mesenchymal stem cells, Umbilical cord mesenchymal stem cells, Human embryonic stem cells, adipose tissue‐derived mesenchymal stem cells, Induced pluripotent stem cells, Neural stem cells, neural progenitor cells, olfactory ensheathing cells, Medial ganglionic eminence‐like progenitor cells which have the potential to remove amyloid depositions in AD brain.
See this image and copyright information in PMC

References

    1. Arvanitakis Z, Shah RC, David A. Bennett diagnosis and management of dementia: a review. JAMA. 2019;322(16):1589‐1599. doi:10.1001/jama.2019.4782 - DOI - PMC - PubMed
    1. Md. Kabir T, Md. Uddin S, Al Mamun A, et al, Combination drug therapy for the Management of Alzheimer's disease Int J Mol Sci 2020;21:3272. doi: 10.3390/ijms21093272 - DOI - PMC - PubMed
    1. Sachdeva P, Ahmad F. In silico characterization of predominant genes involved in early onset Alzheimer's disease. J Neurobehav Sci. 2021;8:179‐190. doi:10.4103/jnbs.jnbs_34_21 - DOI
    1. Walter JL. Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Expert Opin Emerg Drugs. 2012. doi:10.1517/14728214.2012.672559 - DOI - PMC - PubMed
    1. Han S‐H. Inhee Mook‐Jung diverse molecular targets for therapeutic strategies in Alzheimer's disease. J Korean Med Sci. 2014;29:893‐902. doi:10.3346/jkms.2014.29.7.893 - DOI - PMC - PubMed